BioCentury
ARTICLE | Clinical News

Nexavar sorafenib: Completed Phase III enrollment

May 8, 2006 7:00 AM UTC

The partners completed enrollment of about 560 systemic treatment-naïve patients in a double-blind, international Phase III trial. Patients will receive 400 mg twice-daily BAY 43-9006 or placebo. The...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article